A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone

This is a randomized placebo-controlled, parallel-group study, crossover-design of the effects of low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54) This study will assess the impact of LDN compared to placebo on quality of life as measured by the composite score of the MSQOL54 in adult subjects with MS. Also we plan: 1. To compare the 10 scales of the MSQOL54 during the active treatment and placebo cycles between active treatment and placebo groups 2. To compare each individual's composite response to LDN versus placebo during the active treatment and placebo cycles 3. To compare each individual on the 10 scales of the MSQOL54 during the active treatment and placebo cycles